Vantage Biosciences is developing a novel, oral treatment for inflammatory conditions by targeting the root drivers of inflammation. The company focuses on transforming diabetic retinopathy care.

Vantage Biosciences

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Kodiak Sciences Inc Common Stock

Vantage Biosciences | 236 followers on LinkedIn. Transforming diabetic eye disease with an oral treatment | Vantage Biosciences is a UK-based clinical stage biotechnology company targeting the root cause of vision loss resulting from diabetes – the neuroinflammatory insult that precedes microangiopathy and leads to degeneration of the neurovascular unit of the eye. Our mission is to enable patient access to disease modifying therapy for diabetic eye disease by developing drugs that intervene at the earliest point of disease biology.

Very excited at joining the Vantage team as ClinOps VP to forge the way ahead with respect to the treatment of diabetic retinopathy.

Charmaine O'Neill

Biotech VC at ALSA Ventures

Katie Sunnucks

Clinical Project Manager at Vantage Biosciences

Steffy George

Spotlight on Vantage's Co-founder, Graeme Martin! We're thrilled to share a recent presentation by Dr Graeme Martin (PhD) on Oral Therapies for Retina at Ophthalmology Innovation Summit. Check out the presentation here: https://lnkd.in/eh8HsRXt #Ophthalmology #Innovation #VantageBiosciences #OralTherapies #Retina #OIS

We're #hiring a new Clinical Operations Manager in London, England. Apply today or share this post with your network.

Vantage Biosciences will be presenting at the upcoming Ophthalmology Innovation Source in San Diego on December 2nd, 2023. Graeme R. Martin Ph.D. will take the stage to share some exciting news regarding clinical development of VX-01, an oral therapeutic for diabetic retinopathy. This session focused on novel oral treatments for diabetic retinopathy is set to be a highlight of the Summit. Vantage is proud to be at the forefront of significant medical advances for oral treatments for diabetic eye conditions and we are excited to share our progress with the global community. Find out more: https://lnkd.in/dhSsq4MG https://ois.net/ois-xiii/ #VantageBiosciences #OpthalmologyInnovation #DiabeticRetinopathy #ClinicalInnovation #HealthcareEvents

Metric
Company Name	Vantage Biosciences	Kodiak Sciences Inc Common Stock
Symbol		KOD
MSH ID	COM:VANTAGE-BIOSCIENCES	COM:KODIAK
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	GB	US
Stage	Seed
Employee Count		108
Website	vantage-biosciences.com	kodiak.com
LinkedIn	vantage-biosciences
Founders

Metric
Market Cap		325.74M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VANT

COM:VANTAGE-BIOSCIENCES

Vantage Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue